Back to Journals » OncoTargets and Therapy » Volume 7

The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells

Authors Zhang J, Zhou Q, Gao G, Wang Y, Fang Z, Li G, Yu M, Kong L, Xing Y, Gao X

Received 11 May 2014

Accepted for publication 30 July 2014

Published 30 October 2014 Volume 2014:7 Pages 2013—2019

DOI https://doi.org/10.2147/OTT.S67556

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Faris Farassati


Junxia Zhang,1,* Qiang Zhou,2,* Ge Gao,3,* Yanfen Wang,1 Zhihui Fang,1 Guanlin Li,4 Mengfei Yu,5 Lingfei Kong,6 Ying Xing,3 Xiaoqun Gao1

1Department of Anatomy, Basic Medical College, Zhengzhou University, Henan, People’s Republic of China; 2Department of Pathology, Children’s Hospital of Zhengzhou City, Henan, People’s Republic of China; 3Department of Physiology, Basic Medical College, Zhengzhou University, Henan, People’s Republic of China; 4Department of Laboratory, The First Affiliated Hospital of Zhengzhou University, Henan, People’s Republic of China; 5Department of Pharmacy, Zhengzhou Central Hospital, Zhengzhou University, Henan, People’s Republic of China; 6Department of Pathology, Henan Provincial People’s Hospital, Henan, People’s Republic of China

*These authors contributed equally to this work

Abstract: Glioblastoma is one of the most common malignant tumors in the nervous system in both adult and pediatric patients. Studies suggest that abnormal activation of receptor tyrosine kinases contributes to pathological development of glioblastoma. However, current therapies targeting tyrosine kinase receptors have poor therapeutic outcomes. Here, we examined anticancer effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, on glioblastoma cells both in the U87MG cell line and in the mouse xenograft model. We showed that ponatinib treatment reduced cell viability and induced cell apoptosis in a dose-dependent manner in U87MG cells. In addition, ponatinib suppressed migration and invasion of U87MG cells effectively. Furthermore, ponatinib-treated tumors showed an obvious reduction of tumor volume and an increase of apoptosis as compared with vehicle-treated tumors in the mouse xenograft model. These findings support a potential application of ponatinib as a chemotherapeutic option against glioblastoma cells.

Keywords: cancer therapy, glioma, glioblastoma multiforme

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]